Endpoints News
How Seaport is hedging against failure in Phase 2b depression study
Seaport Therapeutics is building a fail-safe into its Phase 2b depression trial.
The biotech is testing its drug, called SPT-300, in patients with major depressive disorder. But executives believe SPT-300 could prove more promising in …